Email updates

Keep up to date with the latest news and content from Malaria Journal and BioMed Central.

This article is part of the supplement: Challenges in malaria research

Open Access Open Badges Oral presentation

Antimalarial drug discovery: targeting the hypnozoite for new radical curative agent

Bryan Yeung

  • Correspondence: Bryan Yeung

Author Affiliations

Novartis Institute for Tropical Diseases, Singapore

Malaria Journal 2012, 11(Suppl 1):O32  doi:10.1186/1475-2875-11-S1-O32

The electronic version of this article is the complete one and can be found online at:

Published:15 October 2012

© 2012 Yeung; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

Plasmodium vivax malaria remains a significant health burden in endemic areas like South East Asia, Central and South America. P. vivax infections are characterized by relapses of malaria caused by persistent liver stages of the parasite (hypnozoites) which are not present in P. falciparum infections. Currently, the only approved treatment option for the radical cure of P. vivax malaria is the 8-aminoquinoline, primaquine. However the long treatment course (two weeks) and severe side effects (hemolytic anemia in G6PD-deficeint patients) highlights the need for new chemical classes of drugs.

Currently the discovery of new anti-hypnozoite drugs is limited to testing in the P. cynomolgi rhesus monkey model. However recently developed assays that allow for the testing of new chemical entities on the parasite liver-stages (schizonts) and sexual stages (gametocytes) could be leveraged to identify dual acting compounds with potental anti-hypnozoite activity. In addition, compounds which target more than one stage in the Plasmodium lifecycle would be highly valued and compliment the current arsenal of antimalarial drugs.